Rybelsus Semaglutide 3 Mg Tablet

₹ 3,170/Strip

strength3 mg
Packaging size10*10 Tablets
Packaging TypeStrip
CompositionSemaglutide
BrandRybelsus 3mg
ManufacturerNovo nordisk
Prescription/Non prescriptionNon prescription
Usuageto treat type 2 diabetes
Prescription / Non PrescriptionNon Prescription
Usage3mg
Also givesPharmaceutical Third Party Manufacturing
Country of OriginMade in India
AvailabilityIn Stock
View in Hindi रायबेलसस सेमाग्लूटाइड 3 एमजी टैबलेट

We “ Velocity Healthcare " are a Wholesaler ,Trader, Distributor and Exporter of an extensive array Pharmaceutical Tablets, Pharmaceutical Injection, Pharmaceutical Capsules etc.

Exports To: United States Of America | Germany | Italy | Spain | France

Find products similar to Rybelsus Semaglutide 3 Mg Tablet

Find related categories

Shipping Information

PriceExcluding all taxes
Ships fromMumbai
ShippingAs per delivery location

Product Image

Rybelsus Semaglutide 3 Mg Tablet image 1Rybelsus Semaglutide 3 Mg Tablet image 2Rybelsus Semaglutide 3 Mg Tablet image 3

About the Company

GST Registration Date
Aug 2021
Legal Status of Firm
Partnership
Nature of Business
Wholesaler/Distributor
Number of Employees
Upto 10 People
Annual Turnover
1.5 - 5 Cr
IndiaMART Member Since
Sept 2018
GST
27**********1ZQ
Import Export Code (IEC)
*******81E
Exports to
United States Of America | Germany | Italy | Spain | France

Established in the year of 2021, We “ Velocity Healthcare " are a Wholesaler ,Trader, Distributor and Exporter of an extensive array Pharmaceutical Tablets, Pharmaceutical Injection, Pharmaceutical Capsules etc. We direct all our activities to cater the expectations of customers by providing them excellent quality products as per their gratification. Moreover, we follow moral business policies and crystal pure transparency in all our transactions to keep healthy relations with the customers. For our accomplishment story, we are grateful to our Mr. Irfan (CEO), whose continual backing and directions have been useful to us for attaining exponential development in the current market.